Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding

Obstetrics and Gynecology

Volumn 90, Issue 2, 1997, Pages 257-263

  Crosignani, Pier Giorgio ^b   Vercellini, Paolo ^a   Mosconi, Paola ^b   Oldani, Sabina ^b   Cortesi, Ilenia ^b   De Giorgi, Olga ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RELEASE; ENDOMETRIUM ABLATION; FEMALE; FOLLOW UP; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; HYSTEROSCOPY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENORRHAGIA; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING;

ADULT; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; HYSTEROSCOPY; INTRAUTERINE DEVICES, MEDICATED; LAPAROSCOPY; LEVONORGESTREL; MENORRHAGIA; MIDDLE AGED; PATIENT SATISFACTION; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; TIME FACTORS;

EID: 0030743584     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00226-3     Document Type: Article

References (24)

1. Scottish Hysteroscopy Audit Group. A Scottish audit of hysteroscopic surgery for menorrhagia: Complications and follow up. Br J Obstet Gynaecol 1995;102:249-54.
2. Andersson K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-4.
3. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-83.
4. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception 1994;49:56-72.
5. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 Mg/d and the Copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. Fertil Steril 1994;61:70-7.
6. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-76.
7. Nilsson CG. Fertility after discontinuation of levonorgestrel-releasing intrauterine devices. Contraception 1982;25:273-8.
8. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.
9. Nilsson CG, Lähteenmäki PLA, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980;21:225-38.
10. Nilsson CG, Lähteenmäki P, Robertson DN, Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol 1980;93:380-4.
11. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982;17:529-36.
12. Higham JM, O'Brien PMS, Shaw RW. Assessment of menstrual blood using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9.
13. Janssen CAH, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995;85:977-82.
14. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
15. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
16. Aaronson NK, Acquadro C, Alonso J, Apolone G, Bucquet D, Bullinger M, et al. International quality of life assessment (IQOLA) project. Qual Life Res 1992;1:349-51.
17. Ware JE, Gandek BL, Keller SD, IQOLA Project Group. Evaluating instruments used cross-nationally: Methods from the IQOLA project. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996;71:681-92.
18. Apolone G, Mosconi P. The Italian SF-36 Health Survey: Translation, validation and norming from a clinical epidemiology perspective. J Clin Epidemiol 1997;50 (in press).
19. Ware JE, Snow KK, Kosinski M, Gaudek B. SF-36 Health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1997.
20. Cronbach LJ, Warrington WG. Time-limit tests: Estimating their reliability and degree of speeding. Psychometrika 1951;314:1657-64.
21. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine device. Int J Gynecol Pathol 1986;5:235-41.
22. Pakarinen P, Luukkainen T, Laine H, Lähteenmäki P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Hum Reprod 1995;10: 2390-4.
23. Nilsson CG, Lähteenmäki P, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1994;41:52-5.
24. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson E. Ovarian function during use of levonorgestrel-releasing IUD. Contraception 1990;42:51-66.